FAP and cancer: As seen in Figure 1A, 125I-FAPI-01 showed no significant binding to the FAP-negative cancer cell lines but targeted human and murine FAP-expressing cells with high affinity (half-maximal inhibitory concentration for human FAP, 39.4 nM).